Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
RAIN-32
DRUG
2 trials
Sponsors
Rain Oncology Inc
Conditions
Adrenocortical Carcinoma
Biliary Tract Cancer
Bladder Urothelial Carcinoma
Breast Cancer Invasive
Cervical Cancer
Cholangiocarcinoma
Dedifferentiated Liposarcoma
Gastric Cancer
+11 more
Phase 2
Milademetan in Advanced/Metastatic Solid Tumors
Terminated
NCT05012397
Rain Oncology Inc
Adrenocortical Carcinoma, Biliary Tract Cancer, Bladder Urothelial Carcinoma +15
Start: 2021-11-01
End: 2023-10-15
Updated: 2024-10-17
Phase 3
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
Terminated
NCT04979442
Rain Oncology Inc
Dedifferentiated Liposarcoma
Start: 2021-07-14
End: 2023-10-01
Updated: 2025-01-14
Related Papers
Abstract B034: A phase 2 basket study of the oral MDM2 inhibitor milademetan for <i>MDM2</i>-amplified advanced solid tumors (MANTRA-2)
Molecular Cancer Therapeutics
2023-12-01
1 citations
Abstract 551: MDM2 inhibition in combination with imipridone ONC201 treatment as a synergistic combination in solid tumors
Cancer Research
2023-04-04
1 citations
Abstract P6-10-10: Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan
Cancer Research
2023-03-01
Abstract 1174: Exploration of MDM2 gene amplification, co-mutation status, and prognosis in solid tumors
Cancer Research
2022-06-15
1 citations
Abstract CT123: A phase 2 study of the MDM2 inhibitor milademetan in patients with <i>TP53-</i>wild type and <i>MDM2</i>-amplified advanced or metastatic solid tumors (MANTRA-2)
Cancer Research
2022-06-15
Abstract CT235: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas
Cancer Research
2022-06-15
A phase 2 study of the MDM2 inhibitor milademetan in patients with <i>TP53</i>-wild type and <i>MDM2</i>-amplified advanced or metastatic solid tumors (MANTRA-2).
Journal of Clinical Oncology
2022-06-01
7 citations
MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas.
Journal of Clinical Oncology
2022-06-01
7 citations